Skip to main content

💊 Pharmaceutical companies

In this section, you will find a list of our major customers in this segment.

  1. Novartis
  2. Almirall
  3. Bella Aurora
  4. Lilly
  5. Ferrer
  6. Boehringer Ingelheim
  7. Pierre Fabre
  8. Galderma

Summary​

Here's a screenshot of our sales pipeline for this segment.

screenshot of our sales pipeline

Almirall​

Diego Herrera (Almirall) & Taig MacCarthy (Legit.Health) Digitalising clinical endpoints with AI

Pharmaceutical companies pain​

Pharmaceutical companies such as Novartis or Almirall face the tough challenge of clinically validating their treatments for skin disorders, such as psoriasis or atopic dermatitis, in order to market them. They must try their drugs in many countries and with many cohorts of patients. Each costs $49.3 million on average (source: ASPE, US, ​Jul 24, 2014), takes around 4 years to complete and requires contracting CROs and expert consultants. This is why pharmas want to run Decentralised Clinical Trials (DCT). It allows recruiting patients remotely, reducing the costs and speeding up the process. However, DCTs still require a lot of human intervention and doctors reviewing all the patients to ensure they fit the inclusion criteria, and to manually assess their severity to measure if the treatment is working. DCTs in dermatology also present the high risk of images taken by patients or doctors not having sufficient quality, which may derail the whole trial.

How Legit.Health is helping​

Pharmaceutical companies will benefit from:

  1. Automatically recruit patients ensuring they match the inclusion criteria thanks to the Diagnosis Support feature and the Automatic Severity Assessment feature.
  2. Automatically fill-in the scoring systems (PASI, SCORAD, UAS…) with an 8% reduction in variability.
  3. The Image Quality Assurance feature ensures that images are of sufficient utility. Our technology is implemented into DCT software to automatically screen patients. This is done at a large scale, remotely through the internet and without manual labout. The solution analyses photos and measures the severity. Also checks that the quality of the photos is enough, prompting the patient to re-take a picture when it’s not.

Thanks to our solution, the pharma company saves cost, reduces risk and improves the speed of their clinical trials, whilst generating additional clinical endpoints in an automatic manner, that provide all data necessary to validate a treatment.